Race Oncology Limited (RAC.AX)
AUD 1.0
(2.04%)
AUD 1.0
(2.04%)
| Year | Operating Income | Operating Income Growth |
|---|---|---|
| 2024 | -13.38 Million AUD | -3.03% |
| 2023 | -12.98 Million AUD | -13.07% |
| 2022 | -11.48 Million AUD | -77.36% |
| 2021 | -6.47 Million AUD | -63.52% |
| 2020 | -3.96 Million AUD | -5.24% |
| 2019 | -3.76 Million AUD | 40.54% |
| 2018 | -6.32 Million AUD | -56.58% |
| 2017 | -4.04 Million AUD | -714.63% |
| 2016 | -496.2 Thousand AUD | -446.95% |
| 2015 | -90.72 Thousand AUD | 4.72% |
| 2014 | -95.21 Thousand AUD | -625.65% |
| 2013 | -13.12 Thousand AUD | 0.0% |
| Year | Operating Income | Operating Income Growth |
|---|---|---|
| 2024 Q2 | -9.61 Million AUD | 0.0% |
| 2024 Q4 | -7.96 Million AUD | 0.0% |
| 2024 FY | -17.83 Million AUD | -37.31% |
| 2023 Q2 | -5.56 Million AUD | 0.0% |
| 2023 FY | -12.98 Million AUD | -13.07% |
| 2023 Q4 | -7.41 Million AUD | 0.0% |
| 2022 Q4 | -6.21 Million AUD | 0.0% |
| 2022 Q2 | -5.27 Million AUD | 0.0% |
| 2022 FY | -11.48 Million AUD | -77.36% |
| 2021 Q2 | -2.36 Million AUD | 0.0% |
| 2021 Q4 | -4.1 Million AUD | 0.0% |
| 2021 FY | -6.47 Million AUD | -63.52% |
| 2020 Q4 | -2.37 Million AUD | 0.0% |
| 2020 FY | -3.96 Million AUD | -5.24% |
| 2020 Q2 | -1.58 Million AUD | 0.0% |
| 2019 FY | -3.76 Million AUD | 40.54% |
| 2019 Q4 | -1.58 Million AUD | 0.0% |
| 2019 Q2 | -2.03 Million AUD | 0.0% |
| 2018 Q2 | -3.49 Million AUD | 0.0% |
| 2018 Q4 | -2.82 Million AUD | 0.0% |
| 2018 FY | -6.32 Million AUD | -56.58% |
| 2017 Q2 | -2.09 Million AUD | 0.0% |
| 2017 FY | -4.04 Million AUD | -714.63% |
| 2017 Q4 | -2.08 Million AUD | 0.0% |
| 2016 Q2 | -168.17 Thousand AUD | 0.0% |
| 2016 FY | -496.2 Thousand AUD | -446.95% |
| 2016 Q4 | -262.41 Thousand AUD | 0.0% |
| 2015 Q3 | - AUD | 100.0% |
| 2015 Q1 | -3233.00 AUD | 0.0% |
| 2015 Q4 | -84.25 Thousand AUD | 0.0% |
| 2015 Q2 | -6466.00 AUD | -100.0% |
| 2015 FY | -90.72 Thousand AUD | 4.72% |
| 2014 FY | -95.21 Thousand AUD | -625.65% |
| 2013 FY | -13.12 Thousand AUD | 0.0% |
| Name | Operating Income | Operating Income Difference |
|---|---|---|
| AdAlta Limited | -5.26 Million AUD | -154.306% |
| Acrux Limited | -9.83 Million AUD | -36.064% |
| Botanix Pharmaceuticals Limited | -14.69 Million AUD | 8.975% |
| BTC Health Limited | 1.05 Million AUD | 1367.954% |
| Chimeric Therapeutics Limited | -12.3 Million AUD | -8.7% |
| Clarity Pharmaceuticals Ltd | -44.8 Million AUD | 70.133% |
| Clinuvel Pharmaceuticals Limited | 49.14 Million AUD | 127.225% |
| Biome Australia Limited | -1.91 Million AUD | -599.366% |
| Hexima Limited | -1 Million AUD | -1226.449% |
| Immutep Limited | -44.93 Million AUD | 70.224% |
| Memphasys Limited | -2.7 Million AUD | -394.843% |
| Neuren Pharmaceuticals Limited | 225.96 Million AUD | 105.922% |
| Noxopharm Limited | -7.53 Million AUD | -77.579% |
| Prescient Therapeutics Limited | -7.18 Million AUD | -86.192% |
| Radiopharm Theranostics Limited | -47.2 Million AUD | 71.657% |
| Starpharma Holdings Limited | -15.15 Million AUD | 11.732% |
| Tissue Repair Ltd | -4.87 Million AUD | -174.419% |
| Biotron Limited | -5.15 Million AUD | -159.758% |
| Alterity Therapeutics Limited | -19.6 Million AUD | 31.738% |
| CSL Limited | 5.64 Billion AUD | 100.237% |
| EZZ Life Science Holdings Limited | 9.71 Million AUD | 237.709% |
| Anatara Lifesciences Ltd | -1.45 Million AUD | -817.025% |
| Bio-Gene Technology Limited | -3.06 Million AUD | -336.921% |
| Zelira Therapeutics Limited | -5.93 Million AUD | -125.329% |
| Patrys Limited | -3.53 Million AUD | -278.073% |
| Orthocell Limited | -11.68 Million AUD | -14.549% |
| Imugene Limited | -140.93 Million AUD | 90.506% |
| PYC Therapeutics Limited | -38.85 Million AUD | 65.565% |
| Proteomics International Laboratories Limited | -7.23 Million AUD | -85.03% |
| Cynata Therapeutics Limited | -8.8 Million AUD | -51.915% |
| Arovella Therapeutics Limited | -7.19 Million AUD | -86.021% |
| Nanollose Limited | -1.24 Million AUD | -970.595% |
| Invex Therapeutics Ltd | -2.13 Million AUD | -527.127% |
| NeuroScientific Biopharmaceuticals Limited | -2.05 Million AUD | -550.628% |
| Amplia Therapeutics Limited | -4.42 Million AUD | -202.387% |
| Island Pharmaceuticals Limited | -2.87 Million AUD | -365.608% |
| Nyrada Inc. | -4.56 Million AUD | -193.412% |
| Telix Pharmaceuticals Limited | - AUD | Infinity% |
| Dimerix Limited | -25.05 Million AUD | 46.605% |
| PharmAust Limited | -6.65 Million AUD | -100.951% |
| AnteoTech Limited | -11.72 Million AUD | -14.104% |
| Paradigm Biopharmaceuticals Limited | -65.11 Million AUD | 79.45% |
| Recce Pharmaceuticals Ltd | -22.05 Million AUD | 39.321% |
| Avecho Biotechnology Limited | -4.58 Million AUD | -191.567% |
| Actinogen Medical Limited | -12.83 Million AUD | -4.218% |
| Immuron Limited | -5.8 Million AUD | -130.655% |
| Argenica Therapeutics Limited | -5.67 Million AUD | -135.939% |